{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-001969","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.631960+00:00","generated_at":"2026-06-27T04:52:17.521818+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alector Q4 2021 net loss $55.6M; cash $735M plus $200M from GSK; pipeline advancing","bullets":["Net loss Q4 2021 $55.6M ($0.68/share) vs $52.2M ($0.66) in Q4 2020; full-year net loss $36.3M ($0.45) vs $190.2M ($2.45).","Collaboration revenue Q4 $14.0M (up from $4.9M); full-year $207.1M (up from $21.1M) driven by GSK deal.","Cash $735.3M at Dec 31, 2021; plus $200M from GSK in Jan 2022. Cash runway expected into mid-2024.","AL002 Phase 2 ARIA observed; protocol amended to exclude APOE e4/e4 homozygotes.","Appointed Sara Kenkare-Mitra (President/Head R&D) and Marc Grasso (CFO)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-001969","json":"https://secwatch.observer/filing/0000950170-22-001969.json","markdown":"https://secwatch.observer/filing/0000950170-22-001969.md","text":"https://secwatch.observer/filing/0000950170-22-001969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017022001969/0000950170-22-001969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017022001969/alec-20220224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:52:17.521818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}